Business Description
Athira Pharma Inc
NAICS : 541714
SIC : 2833
ISIN : US04746L1044
Share Class Description:
ATHA: Ordinary SharesDescription
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 52.4 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -26.5 | |||||
| 3-Year EPS without NRI Growth Rate | -24.5 | |||||
| 3-Year FCF Growth Rate | -6.4 | |||||
| 3-Year Book Growth Rate | -26.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 35.39 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.82 | |||||
| 9-Day RSI | 52.79 | |||||
| 14-Day RSI | 51.21 | |||||
| 6-1 Month Momentum % | -81.02 | |||||
| 12-1 Month Momentum % | -65.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.95 | |||||
| Quick Ratio | 2.95 | |||||
| Cash Ratio | 2.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | 1.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -102.53 | |||||
| ROA % | -80.8 | |||||
| ROIC % | -1255.26 | |||||
| ROC (Joel Greenblatt) % | -2697.54 | |||||
| ROCE % | -103.91 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.44 | |||||
| Price-to-Tangible-Book | 0.44 | |||||
| EV-to-EBIT | 0.38 | |||||
| EV-to-EBITDA | 0.38 | |||||
| EV-to-FCF | 0.43 | |||||
| Price-to-Net-Current-Asset-Value | 0.47 | |||||
| Price-to-Net-Cash | 0.63 | |||||
| Earnings Yield (Greenblatt) % | 263.16 | |||||
| FCF Yield % | -384.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATHA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Athira Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.85 | ||
| Beta | 2.61 | ||
| Volatility % | 143.54 | ||
| 14-Day RSI | 51.21 | ||
| 14-Day ATR ($) | 0.07039 | ||
| 20-Day SMA ($) | 0.67278 | ||
| 12-1 Month Momentum % | -65.54 | ||
| 52-Week Range ($) | 0.4115 - 4.2984 | ||
| Shares Outstanding (Mil) | 38.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Athira Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Athira Pharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Athira Pharma Inc Frequently Asked Questions
What is Athira Pharma Inc(ATHA)'s stock price today?
The current price of ATHA is $0.66. The 52 week high of ATHA is $4.30 and 52 week low is $0.41.
When is next earnings date of Athira Pharma Inc(ATHA)?
The next earnings date of Athira Pharma Inc(ATHA) is 2025-02-21 Est..
Does Athira Pharma Inc(ATHA) pay dividends? If so, how much?
Athira Pharma Inc(ATHA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers